OncoCyte Corp reports results for the quarter ended March 31 - Earnings Summary

• OncoCyte Corp OCX.OQ reported a quarterly adjusted loss of 26 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.13. The mean expectation of four analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -25 cents to -22 cents per share.

• Revenue rose 1,114.8% to $2.14 million from a year ago; analysts expected $126.75 thousand.

• OncoCyte Corp's reported EPS for the quarter was a loss of 26 cents​.

• The company reported a quarterly loss of $6.67 million.

• OncoCyte Corp shares had fallen by 6.2% this quarter and gained 20.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 43.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "hold."

• Wall Street's median 12-month price target for OncoCyte Corp is $4.50

This summary was machine generated from LSEG data May 13 at 12:01 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)